Zoetis Inc. (ZTS): Price and Financial Metrics
Zoetis Inc. (ZTS)
Today's Latest Price: $160.96 USD
Updated Oct 29 1:44pm
Add ZTS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ZTS Stock Summary
- ZTS has a market capitalization of $75,400,713,078 -- more than approximately 97.61% of US stocks.
- ZTS's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 325.04 -- higher than 90.11% of US-listed equities with positive expected earnings growth.
- Price to trailing twelve month operating cash flow for ZTS is currently 38.99, higher than 91.08% of US stocks with positive operating cash flow.
- If you're looking for stocks that are quantitatively similar to Zoetis Inc, a group of peers worth examining would be BDX, SYK, CAT, SE, and MELI.
- Visit ZTS's SEC page to see the company's official filings. To visit the company's web site, go to www.zoetis.com.
ZTS Stock Price Chart Interactive Chart >
ZTS Price/Volume Stats
| Current price | $160.96 | 52-week high | $168.96 |
| Prev. close | $158.69 | 52-week low | $90.14 |
| Day low | $158.13 | Volume | 723,776 |
| Day high | $160.96 | Avg. volume | 2,077,812 |
| 50-day MA | $161.07 | Dividend yield | 0.5% |
| 200-day MA | $141.43 | Market Cap | 76.48B |
Zoetis Inc. (ZTS) Company Bio
Zoetis Inc. discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. The company was founded in 1952 and is based in Florham Park, New Jersey.
ZTS Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $160.96 | $73.98 | -53% |
We started the process of determining a valid price forecast for Zoetis Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Zoetis Inc ranked in the 28th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Zoetis Inc, consider:
- As a business, ZTS is generating more cash flow than 82.97% of positive cash flow stocks in the Healthcare.
- The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than only 22.01% of the free cash flow producing stocks we're observing.
- ZTS's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 37.46% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -54% |
| 1% | -54% |
| 2% | -53% |
| 3% | -53% |
| 4% | -52% |
| 5% | -52% |
LMAT, CPIX, ILMN, JNJ, and HAPP can be thought of as valuation peers to ZTS, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...